{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:24:03Z","timestamp":1760297043725},"publisher-location":"Chichester, UK","reference-count":92,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd001417","type":"reference-entry","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:16:04Z","timestamp":1069384564000},"source":"Crossref","is-referenced-by-count":17,"title":["Topiramate add-on for drug-resistant partial epilepsy"],"prefix":"10.1002","author":[{"given":"N","family":"Jette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Hemming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JL","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AG","family":"Marson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,7,22]]},"reference":[{"key":"10.1002\/14651858.CD001417-BIB3|cit1","series-title":"Epilepsia","first-page":"S150","article-title":"Double-blind, placebo-controlled trial of 800 mg\/day topiramate as add-on therapy in patients with refractory partial epilepsy","author":"Ben-Menachem","year":"1995"},{"key":"10.1002\/14651858.CD001417-BIB2|cit2","series-title":"Epilepsia","first-page":"109","article-title":"Topiramate add-on treatment in patients with intractable partial epilepsy: a multicenter study","author":"Ben-Menachem","year":"1993"},{"key":"10.1002\/14651858.CD001417-BIB1|cit3","series-title":"Epilepsia","first-page":"539","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","author":"Ben-Menachem","year":"1996"},{"key":"10.1002\/14651858.CD001417-BIB4|cit4","series-title":"Epilepsia","first-page":"S149","article-title":"Double-blind, placebo-controlled trial of 400 mg\/day topiramate as add-on therapy in patients with refractory partial epilepsy","author":"Martinez-Lage","year":"1995"},{"key":"10.1002\/14651858.CD001417-BIB5|cit5","series-title":"Epilepsia","first-page":"105","article-title":"Topiramate as add-on therapy in refractory partial epilepsy","author":"Ostergard","year":"1992"},{"key":"10.1002\/14651858.CD001417-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1212\/WNL.52.7.1338","article-title":"A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children","volume":"52","author":"Elterman","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001417-BIB8|cit7","series-title":"Epilepsia","first-page":"33","article-title":"Topiramate dose-ranging trial in refractory partial epilepsy","author":"Faught","year":"1995"},{"key":"10.1002\/14651858.CD001417-BIB7|cit8","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages","volume":"46","author":"Faught","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001417-BIB9|cit9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1600-0404.2002.02071.x","article-title":"Low-Dose topiramate in adults with treatment-resistant partial-onset seizures","volume":"106","author":"Guberman","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1002\/14651858.CD001417-BIB10|cit10","series-title":"Epilepsia","first-page":"179","article-title":"Efficacy of 200 mg\/day topiramate in treatment-resistant partial seizures when added to an enzyme-inducing anti-epileptic drug (AED)","author":"Guberman","year":"2001"},{"key":"10.1002\/14651858.CD001417-BIB11|cit11","series-title":"Epilepsia","first-page":"35","article-title":"Efficacy and tolerability of 200 mg\/day topiramate in a placebo-controlled comparison of titration rates","author":"Neto","year":"2000"},{"key":"10.1002\/14651858.CD001417-BIB12|cit12","series-title":"Epilepsia","first-page":"152","article-title":"Weight reduction during topiramate treatment of partial seizures","author":"Oene","year":"2002"},{"issue":"12","key":"10.1002\/14651858.CD001417-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1528-1157.1999.tb01596.x","article-title":"Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial","volume":"40","year":"1999","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417-BIB14|cit14","first-page":"809","article-title":"Double-blind placebo-controlled randomized clinical trial of topiramate add-on therapy in medically intractable partial epilepsies","volume":"16","author":"Lee","year":"1998","journal-title":"Korean Neurol Assoc"},{"key":"10.1002\/14651858.CD001417-BIB16|cit15","series-title":"Epilepsia","first-page":"33","article-title":"Dose-ranging trial with higher doses of topiramate in patients with resistant partial seizures","author":"Privitera","year":"1995"},{"key":"10.1002\/14651858.CD001417-BIB15|cit16","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/WNL.46.6.1678","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages","volume":"46","author":"Privitera","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001417-BIB17|cit17","series-title":"Epilepsia","first-page":"153","article-title":"Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset seizures","author":"Rosenfeld","year":"1996"},{"key":"10.1002\/14651858.CD001417-BIB18|cit18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(96)00029-0","article-title":"Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy","volume":"25","author":"Sharief","year":"1996","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001417-BIB19|cit19","series-title":"Epilepsia","first-page":"41","article-title":"Adjuvant topiramate treatment in intractable partial epilepsy","author":"Sharief","year":"1993"},{"key":"10.1002\/14651858.CD001417-BIB21|cit20","series-title":"Epilepsia","first-page":"S150","article-title":"Double-blind, placebo-controlled trial of 600 mg\/day topiramate as add-on therapy in patients with refractory partial epilepsy","author":"Tassinari","year":"1995"},{"issue":"8","key":"10.1002\/14651858.CD001417-BIB20|cit21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1528-1157.1996.tb00649.x","article-title":"Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy","volume":"37","author":"Tassinari","year":"1996","journal-title":"Epilepsia"},{"issue":"9","key":"10.1002\/14651858.CD001417-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1528-1157.2000.tb00321.x","article-title":"A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy","volume":"41","author":"Yen","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417-BIB23|cit23","series-title":"Epilepsia","first-page":"94","article-title":"A randomized observer-blind clinical study comparing the cognitive effects of topiramate versus valproate in a first-line add-on design","author":"Aldenkamp","year":"1999"},{"issue":"9","key":"10.1002\/14651858.CD001417-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1528-1157.2000.tb00322.x","article-title":"A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures","volume":"41","author":"Aldenkamp","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417-BIB25|cit25","series-title":"Epilepsia","first-page":"42","article-title":"Topiramate as first-line therapy in newly diagnosed epilepsy characterized by partial-onset or primary generalized tonic-clonic seizures","author":"Arroyo","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB26|cit26","series-title":"Acta Neurologica Scandinavica","first-page":"214","article-title":"Randomized dose-controlled study of topiramate as first-line therapy in epilepsy","author":"Arroyo","year":"2005"},{"key":"10.1002\/14651858.CD001417-BIB27|cit27","series-title":"Epilepsia","first-page":"78","article-title":"Topiramate effective as first line therapy in children\/adolescents with newly diagnosed epilepsy","author":"Barrera","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB28|cit28","series-title":"Epilepsia","first-page":"60","article-title":"A double-blind trial of topiramate in patients with generalized tonic-clonic seizures of non-focal origin","author":"Ben-Menachem","year":"1997"},{"key":"10.1002\/14651858.CD001417-BIB29|cit29","series-title":"Epilepsia","first-page":"274","article-title":"Response to topiramate (TPM), carbamazepine (CBZ) or valproate (VPA) by seizure type in newly diagnosed epilepsy","author":"Ben-Menachem","year":"2005"},{"key":"10.1002\/14651858.CD001417-BIB30|cit30","series-title":"Epilepsy Research","first-page":"31","article-title":"Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)","author":"Bialer","year":"2002"},{"key":"10.1002\/14651858.CD001417-BIB31|cit31","series-title":"Epilepsy Research","first-page":"1","article-title":"Progress report on new antiepileptic drugs: a summary of the seventh Eilat conference (EILAT VII)","author":"Bialer","year":"2004"},{"key":"10.1002\/14651858.CD001417-BIB32|cit32","series-title":"Epilepsia","first-page":"5","article-title":"Comparison of two upward titration rates in initiation of therapy with topiramate","author":"Biton","year":"1996"},{"key":"10.1002\/14651858.CD001417-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.52.7.1330","article-title":"A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures","volume":"52","author":"Biton","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001417-BIB34|cit34","series-title":"Annals of Pharmacotherapy","first-page":"173","article-title":"Topiramate titration and tolerability","author":"Biton","year":"2001"},{"key":"10.1002\/14651858.CD001417-BIB35|cit35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000232737.72555.06","article-title":"Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy","volume":"67","author":"Blum","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001417-BIB36|cit36","series-title":"Epilepsia","first-page":"60","article-title":"Topiramate as long-term therapy in generalized tonic-clonic seizures of non-focal origin","author":"Brodie","year":"1997"},{"key":"10.1002\/14651858.CD001417-BIB37|cit37","series-title":"Epilepsia","first-page":"178","article-title":"Topiramate add-on treatment in refractory epilepsy patients: a randomized concentration-controlled clinical trial","author":"Christensen","year":"2001"},{"key":"10.1002\/14651858.CD001417-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000091867.09720.6B","article-title":"Randomized, concentration-controlled trail of topiramate in refractory focal epilepsy","volume":"61","author":"Christensen","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001417-BIB39|cit39","series-title":"Epilepsia","first-page":"285","article-title":"Seizure severity in patients with partial onset (POS) or primary generalised tonic-clonic (PGTC) seizures following treatment with topiramate. A comparison of two different methodologies in a randomised controlled trial","author":"Coles","year":"1999"},{"key":"10.1002\/14651858.CD001417-BIB40|cit40","series-title":"Epilepsy","first-page":"147","article-title":"Topiramate as as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study","author":"Coppola","year":"2002"},{"article-title":"Neurobehavioral adverse events (AES) with topiramate monotherapy in children and adolescents","series-title":"Epilepsia","author":"Dlugos","key":"10.1002\/14651858.CD001417-BIB41|cit41"},{"key":"10.1002\/14651858.CD001417-BIB42|cit42","series-title":"Epilepsia","first-page":"59","article-title":"Assessment of efficacy and tolerability of topiramate in slow versur rapid titration","author":"Edwards","year":"1997"},{"key":"10.1002\/14651858.CD001417-BIB43|cit43","series-title":"Epilepsia","first-page":"S127","article-title":"Topiramate (TPM) vs Carbamazepine (CBZ) and valproate (VPA) in newly diagnosed epilepsy: effectiveness according to seizure type","author":"Edwards","year":"2004"},{"key":"10.1002\/14651858.CD001417-BIB44|cit44","series-title":"Epilepsia","first-page":"100","article-title":"Tolerability and safety on topiramate as first line monotherapy in 1,000+ epilepsy patients","author":"Faught","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB45|cit45","series-title":"Epilepsy & Behavior","first-page":"373","article-title":"Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy","author":"Fritz","year":"2005"},{"key":"10.1002\/14651858.CD001417-BIB46|cit46","series-title":"Neurology","first-page":"196","article-title":"A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy","author":"Gilliam","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB47|cit47","series-title":"Epilepsia","first-page":"S86","article-title":"Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group","author":"Glauser","year":"2000"},{"key":"10.1002\/14651858.CD001417-BIB48|cit48","series-title":"Epilepsia","first-page":"176","article-title":"Double-blind evaluation of the cognitive effects of lamotrigine versus topiramate adjunctive therapy","author":"Isojarvi","year":"2005"},{"key":"10.1002\/14651858.CD001417-BIB49|cit49","series-title":"Epilepsia","first-page":"38","article-title":"Efficacy of therapy with new antiepileptic drugs (tiagabine, gabapentin, topiramate) in drug-resistant epilepsy","author":"Kazibutowska","year":"2000"},{"key":"10.1002\/14651858.CD001417-BIB50|cit50","series-title":"Epilepsia","first-page":"162","article-title":"Evaluation of the Cognitive Effects of Lamotrigine Versus Topiramate Adjunctive Therapy in Older Adult Patients with Epilepsy","author":"Kerls","year":"2006"},{"key":"10.1002\/14651858.CD001417-BIB51|cit51","series-title":"Epilepsia","first-page":"267","article-title":"Topiramate versus valproate in patients with juvenile myoclonic epilepsy","author":"Levisohn","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB52|cit52","series-title":"Epilepsia","first-page":"322","article-title":"Low-dose topiramate compared with carbamazepine in treating benign rolandic epilepsy","year":"2004"},{"key":"10.1002\/14651858.CD001417-BIB53|cit53","series-title":"Epilepsia","first-page":"151","article-title":"Time-course of adverse events (AE) during topiramate (TPM) in carbamazepine-refractory partial onset epllepsy","author":"J.","year":"2002"},{"key":"10.1002\/14651858.CD001417-BIB55|cit54","series-title":"Epilepsia","first-page":"272","article-title":"Carbamazepine versus gabapentin, lamotrigine, oxcarbazepine and topiramate for epilepsy: results from arm A of the SANAD trial","author":"Marson","year":"2006"},{"issue":"9566","key":"10.1002\/14651858.CD001417-BIB54|cit55","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomized controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001417-BIB57|cit56","series-title":"Lancet","first-page":"1016","article-title":"the SANAD study of effectiveness of valproate, lamotrigine or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","author":"Marson","year":"2007"},{"key":"10.1002\/14651858.CD001417-BIB56|cit57","series-title":"Epilepsia","first-page":"274","article-title":"Valproate versus lamotrigine and topiramate for epilepsy: results from arm B of the SANAD trial","author":"Smith","year":"2006"},{"key":"10.1002\/14651858.CD001417-BIB58|cit58","series-title":"Epilepsia","first-page":"126","article-title":"Tlagabine and topiramate in vigahatrine substitution in epilepsy patients","author":"Martin","year":"2002"},{"key":"10.1002\/14651858.CD001417-BIB60|cit59","series-title":"Epilepsia","first-page":"113","article-title":"Topiramate or valproate added to carbamazepine in adults with epilepsy: effects on subjective and objective measures of cognitive function","author":"Loring","year":"2000"},{"key":"10.1002\/14651858.CD001417-BIB59|cit60","series-title":"Neurology","first-page":"1483","article-title":"Differential cognitive and behavioral effects of topiramate and valproate","author":"Meador","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB61|cit61","series-title":"Epilepsia","first-page":"143","article-title":"Tolerability and efficacy of topiramate in older patients","author":"Mehta","year":"2001"},{"key":"10.1002\/14651858.CD001417-BIB62|cit62","series-title":"Epilepsia","first-page":"165","article-title":"Efficacy and Tolerability of Topiramate in the Elderly Population","author":"Mehta","year":"2002"},{"key":"10.1002\/14651858.CD001417-BIB63|cit63","series-title":"Epilepsia","first-page":"S150","article-title":"Topiramate in the treatment of refractory partial epilepsy: a double-blind study with long-term follow-up","author":"Michelucci","year":"1995"},{"key":"10.1002\/14651858.CD001417-BIB64|cit64","series-title":"Epilepsia","first-page":"70","article-title":"Topiramate in the treatment of refractory epilepsy: a 2 year long-term follow-up","author":"Michelucci","year":"1996"},{"key":"10.1002\/14651858.CD001417-BIB65|cit65","series-title":"Epilepsia","first-page":"S77","article-title":"Nonfocal generalized tonic-clonic seizures: response during long-term topiramate treatment. Topiramate YTC\/YTCE study group","author":"Montouris","year":"2000"},{"key":"10.1002\/14651858.CD001417-BIB66|cit66","series-title":"Epilepsia","first-page":"268","article-title":"Topiramate monotherapy: interim blinded data from a study in elderly patients","author":"Morgenroth","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB67|cit67","series-title":"The Annals of Pharmacother","first-page":"418","article-title":"Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial","author":"Naritoku","year":"2005"},{"key":"10.1002\/14651858.CD001417-BIB68|cit68","series-title":"Epilepsia","first-page":"138","article-title":"Monotherapy in newly diagnosed epilepsy: topiramate vs investigator choice of carbamazepine or valproate","author":"Privitera","year":"2000"},{"key":"10.1002\/14651858.CD001417-BIB69|cit69","series-title":"Epilepsia","first-page":"270","article-title":"100 mg\/day topiramate as the initial target dose in newly diagnosed epilepsy","author":"Privitera","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB70|cit70","series-title":"Acta Neurologica Scandinavica","first-page":"165","article-title":"Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy","author":"Privitera","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB71|cit71","series-title":"Epilepsia","first-page":"183","article-title":"Interim safety analysis from a study of topiramate in the treatment of seizures in elderly patient","author":"Pryor","year":"2002"},{"key":"10.1002\/14651858.CD001417-BIB72|cit72","series-title":"Epilepsia","first-page":"114","article-title":"Topiramate (TPM) in older adults with partial-onset seizures: a double-blind, dose-comparison study","author":"Ramsay","year":"2005"},{"key":"10.1002\/14651858.CD001417-BIB73|cit73","series-title":"Epilepsia","first-page":"93","article-title":"Topiramate as first-line therapy: findings from children\/adolescents with newly diagnosed epilepsy","author":"Rho","year":"2003"},{"issue":"1","key":"10.1002\/14651858.CD001417-BIB74|cit74","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1111\/j.1528-1157.2000.tb02178.x","article-title":"Effectiveness, Tolerability, and Safety of Topiramate in Children with Partial-Onset Seizures","volume":"41","author":"Ritter","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417-BIB75|cit75","series-title":"Epilepsia","first-page":"82","article-title":"Topiramate in newly diagnosed epilepsy: 100 mg\/day as initial target dose","author":"Sander","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB76|cit76","unstructured":"Shields WD Phase III randomized, double-blind, placebo-controlled study of oral topiramate for Lennox-Gastaut syndrome www.clinicaltrials.gov\/ct\/show\/NCT00004776 2004"},{"key":"10.1002\/14651858.CD001417-BIB77|cit77","series-title":"Epilepsia","first-page":"80","article-title":"Double-blind placebo-controlled trial of topiramate in refractory partial epilepsy with open-label concentration","author":"Walker","year":"1996"},{"key":"10.1002\/14651858.CD001417-BIB78|cit78","series-title":"Epilepsy Research","first-page":"271","article-title":"Topiramate on ictal seizure semiology: a quantitative, randomized, low and medium dose-controlled study","author":"Wang","year":"2001"},{"issue":"2","key":"10.1002\/14651858.CD001417-BIB79|cit79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0920-1211(02)00014-1","article-title":"Clinical effects of topiramate against secondarily generalized tonic-clonic seizures","volume":"49","author":"Wang","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1002\/14651858.CD001417-BIB80|cit80","series-title":"Epilepsia","first-page":"273","article-title":"Topiramate as first-line therapy in newly diagnosed epilepsy characterized by partial onset or primary generalized tonic-clonic seizures","author":"Wheless","year":"2003"},{"key":"10.1002\/14651858.CD001417-BIB81|cit81","series-title":"Journal of Child Neurology","first-page":"135","article-title":"Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy","author":"Wheless","year":"2004"},{"key":"10.1002\/14651858.CD001417-BIB83|cit82","series-title":"Epilepsia","first-page":"150","article-title":"A randomized placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability","author":"Kerr","year":"2004"},{"key":"10.1002\/14651858.CD001417-BIB82|cit83","series-title":"Epilepsia Behavior","first-page":"472","article-title":"A randomized double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life","author":"Kerr","year":"2005"},{"key":"10.1002\/14651858.CD001417-BIB84|cit84","unstructured":"Anonymous A randomized, double-blind, placebo-controlled, fixed dose-ranging study to assess the safety, tolerability, and efficacy of topiramate oral liquid and sprinkle formulations as an adjunct to concurrent anticonvulsant therapy for infants (1-23 months of age, inclusive) with refractory, partial-onset seizures, with open-label extension"},{"key":"10.1002\/14651858.CD001417-BIB85|cit85","unstructured":"Brown SD Wolf HH Swinyard EA The novel anticonvulsant topiramate enhances GABA-mediated chloride flux Epilepsia 1993 122"},{"key":"10.1002\/14651858.CD001417-BIB86|cit86","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the national general practice study of epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001417-BIB87|cit87","unstructured":"Coulter DA Sombati S DeLorenzo RJ Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons Epilepsia 1993 123"},{"key":"10.1002\/14651858.CD001417-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1975.tb04721.x","article-title":"The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967","volume":"16","author":"Hauser","year":"1975","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417-BIB89|cit89","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized linear models","author":"McCullagh","year":"1989"},{"key":"10.1002\/14651858.CD001417-BIB90|cit90","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1157.1981.tb06158.x","article-title":"Phenytoin for epilepsy: a long term prospective study, assisted by serum level monitoring in previously untreated patients","volume":"22","author":"Reynolds","year":"1981","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417-BIB91|cit91","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.313.7066.1169","article-title":"New antiepileptic drugs; a systematic review of their efficacy and tolerability","volume":"313","author":"Marson","year":"1996","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001417-BIB92|cit92","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs; a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:02:49Z","timestamp":1628542969000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001417"}},"subtitle":[],"editor":[{"given":"Nathalie","family":"Jette","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2002,7,22]]},"references-count":92,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001417","relation":{},"subject":[],"published":{"date-parts":[[2002,7,22]]}}}